Vanguard Group Inc. Buys 1,115,337 Shares of Boston Scientific Corporation $BSX

Vanguard Group Inc. lifted its position in Boston Scientific Corporation (NYSE:BSX) by 0.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 138,249,447 shares of the medical equipment provider’s stock after acquiring an additional 1,115,337 shares during the quarter. Vanguard Group Inc. owned 9.33% of Boston Scientific worth $13,497,294,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BSX. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter valued at about $26,000. Steph & Co. purchased a new position in Boston Scientific during the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific in the 3rd quarter worth approximately $25,000. Finally, United Community Bank lifted its position in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the period. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research reports. Wells Fargo & Company reduced their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Morgan Stanley reduced their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. The Goldman Sachs Group set a $99.00 target price on shares of Boston Scientific in a research note on Thursday, February 5th. Finally, UBS Group lowered their price objective on Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $109.43.

Boston Scientific Trading Up 0.8%

Shares of NYSE BSX opened at $74.72 on Monday. The stock has a market capitalization of $110.76 billion, a PE ratio of 38.51, a PEG ratio of 1.03 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $90.93 and a 200-day simple moving average of $97.56. Boston Scientific Corporation has a twelve month low of $72.69 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the firm posted $0.70 EPS. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.